Core Insights - MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for endocrine and metabolic disorders [1][3] - The company will present at the 37th Annual Piper Sandler Healthcare Conference on December 2-4, 2025 [1][2] Company Overview - MBX Biosciences utilizes its proprietary PEP™ platform to discover and develop novel peptide therapies [3] - The company has a pipeline that includes canvuparatide (MBX 2109) for chronic hypoparathyroidism and imapextide (1416) for post-bariatric hypoglycemia, both in Phase 2 development [3] - An obesity portfolio is also in development, including MBX 4291 in Phase 1 and several pre-clinical candidates [3] - The company is based in Carmel, Indiana [3]
MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference